PRDFPartial Response Digital Filter
PRDFPhoenix Raw Data File
PRDFProsperity Russia Domestic Fund Ltd. (UK)
PRDFPels Rijcken & Drooglever Fortuijn (law firm; Netherlands)
PRDFPartial Radial Distribution Function (nuclear energy)
PRDFParticipatory Rural Development Foundation (Gorakhpur, India experimental seed development and testing company)
PRDFPropellant Disposition Facility
PRDFPartitioned Real-Space Density Functional (physics)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The sample size necessary to demonstrate a statistical superiority, based on the hypothesis that one or both drugs can improve the historically documented PRDFS rate of 12% up to approximately 35%, was estimated to require 18 patients per arm, assuming an alpha error level 5% and a power of 81%.
The evaluation of the primary endpoint PRDFS rate was performed as comparison of the 12-month PRDFS rate with the fixed value of 12% (i.e., the average PRDFS rate after second relapse in historical control groups) using an exact Binomial test [28].
After one year of treatment PRDFS rate in Viscum arm was 55.6%, compared to historical 12% rate: P = 0.0041; 95% CI (21.2%; 86.3%) (five out of nine patients) and it was 27.3%, P = 0.2724; 95% CI (6.0%; 61.0%) for Etoposide arm (three out of eleven patients) (see Figure 1).
Until July 2013 in the Viscum arm the median PRDFS (including censored dates) is 39 months (range 2-73 months).
The treatment of relapsed osteosarcoma patients is unsatisfactory especially after a second or further relapse because there is no effective adjuvant treatment besides surgery that can prolong PRDFS. In addition to this, heavily pretreated patients often do not want to receive another aggressive treatment with serious side effects.